Abstract
Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.
Keywords:
antigenic match; clade; genetic sequencing; influenza; vaccine effectiveness.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antigens, Viral / analysis
-
Canada / epidemiology
-
Child
-
Child, Preschool
-
Female
-
Genotype
-
Hemagglutination Inhibition Tests
-
Humans
-
Infant
-
Influenza A Virus, H1N1 Subtype / genetics
-
Influenza A Virus, H1N1 Subtype / immunology
-
Influenza A Virus, H1N1 Subtype / isolation & purification*
-
Influenza A Virus, H3N2 Subtype / genetics
-
Influenza A Virus, H3N2 Subtype / immunology
-
Influenza A Virus, H3N2 Subtype / isolation & purification*
-
Influenza B virus / genetics
-
Influenza B virus / immunology
-
Influenza B virus / isolation & purification*
-
Influenza Vaccines / administration & dosage*
-
Influenza Vaccines / immunology
-
Influenza, Human / epidemiology*
-
Influenza, Human / prevention & control*
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Nasopharynx / virology
-
Nose / virology
-
Real-Time Polymerase Chain Reaction
-
Seasons
-
Sentinel Surveillance
-
Sequence Analysis, DNA
-
Young Adult
Substances
-
Antigens, Viral
-
Influenza Vaccines